Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biogen
5
×
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
5
×
indiana blog main
indiana top stories
life sciences
medicare
5
×
national
national blog main
national top stories
new york blog main
new york top stories
novartis
5
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
5
×
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
deals
gene therapy
alzheimer's disease
cancer
cancer immunotherapy
celgene
crispr
drug prices
glaxosmithkline
ipo
What
bio
roundup
drug
companies
crispr
gene
new
patients
price
remains
talk
acquisitions
albert
allogene
alzheimer’s
approval
becker
biggest
billions
biogen’s
biopharmaceutical
bourla
cancer
ceo
company
convo
different
diversity
dollars
earlier
eaton
fail
failures
future
healthcare
hot
immunotherapy
impact
imports
increases
Language
unknown
Current search:
novartis
×
biogen
×
" detroit top stories "
×
" san francisco top stories "
×
medicare
×
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More